EYEN Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology...

Stats
Tagesvolumen	907 216
Durchschnittsvolumen	1.28M
Marktkapitalisierung	36.29M
EPS	$0 ( 2024-03-18 )
Nächstes Ertragsdatum	( $-0.250 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.080
ATR14	$0.00300 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Grant Stuart M.	Buy	100 000	Common stock, par value $0.0001
2024-03-19	Grant Stuart M.	Buy	50 000	Common stock, par value $0.0001
2024-03-08	Grant Stuart M.	Buy	10 717	Common stock, par value $0.0001
2024-02-12	Gandolfo John P	Buy	60 000	Stock Option (right to buy)
2024-02-12	Rowe Michael M	Buy	75 000	Stock Option (right to buy)

INSIDER POWER
69.07
Last 95 transactions
Buy: 2 919 948 \| Sell: 334 000

Volumen Korrelation

Lang: 0.29 (neutral)

Kurz: -0.14 (neutral)

Signal:(51.794) Neutral

Eyenovia Inc Korrelation

10 Am meisten positiv korreliert
WINA	0.968
INZY	0.966
AMTBB	0.961
CSPI	0.955
TAYD	0.95
SVFAU	0.948
SVFA	0.947
HROW	0.946
BRLI	0.944
HSKA	0.944

10 Am meisten negativ korreliert
CYRN	-0.957
TLGT	-0.936
GNTY	-0.935
FVCB	-0.934
ONEM	-0.933
RPRX	-0.93
PEAR	-0.93
VORB	-0.929
BWB	-0.929
AROW	-0.927

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Eyenovia Inc Korrelation - Währung/Rohstoff

0.00
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.72
( moderate negative )

0.40
( neutral )

Eyenovia Inc Finanzdaten

Annual	2023
Umsatz:	$3 787.00
Bruttogewinn:	$-783 208 (-20 681.49 %)
EPS:	$-0.660

FY	2023
Umsatz:	$3 787.00
Bruttogewinn:	$-783 208 (-20 681.49 %)
EPS:	$-0.660

FY	2022
Umsatz:	$0
Bruttogewinn:	$-307 430 (0.00 %)
EPS:	$-0.820

FY	2021
Umsatz:	$14.00M
Bruttogewinn:	$12.40M (88.57 %)
EPS:	$-0.607

Financial Reports:

No articles found.

Eyenovia Inc

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.